Advertisement
Screener

uniQure N.V. (QURE) Derivative, Gain (Loss) on Derivative, Net

1.8 / 5 stars · 28/79 Roast Me

uniQure N.V. Derivative, Gain (Loss) on Derivative, Net

uniQure N.V. (QURE) reported Derivative, Gain (Loss) on Derivative, Net of $0 for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.

Discontinued › Income Statement › Other Income

us-gaap:DerivativeGainLossOnDerivativeNet · last filed 2022-11-02

  • uniQure N.V. derivative, gain (loss) on derivative, net for the quarter ending 2022-09-30 was $0.00.
  • uniQure N.V. derivative, gain (loss) on derivative, net for the quarter ending 2022-06-30 was $17.14M, a 147.01% increase year-over-year.
  • uniQure N.V. derivative, gain (loss) on derivative, net for the quarter ending 2022-03-31 was $7.36M, a 37.70% increase year-over-year.
  • uniQure N.V. derivative, gain (loss) on derivative, net for the quarter ending 2021-12-31 was $31.34M.
  • uniQure N.V. derivative, gain (loss) on derivative, net for fiscal 2021 was $31.34M.
  • uniQure N.V. derivative, gain (loss) on derivative, net for fiscal 2020 was -$14.73M.
  • uniQure N.V. derivative, gain (loss) on derivative, net for fiscal 2019 was -$891.00K, a 116.19% decline from fiscal 2018.
  • uniQure N.V. derivative, gain (loss) on derivative, net for fiscal 2018 was $5.50M.
Period endDerivative, Gain (Loss) on Derivative, Net 3 monthDerivative, Gain (Loss) on Derivative, Net 6 monthDerivative, Gain (Loss) on Derivative, Net 9 monthDerivative, Gain (Loss) on Derivative, Net 9 month as first filedDerivative, Gain (Loss) on Derivative, Net 12 month
2022-09-30$0.00
10-Q · filed 2022-11-02
$17.14M
derived: sum of 2 quarters · filed 2022-11-02
$600.00K
10-Q · filed 2022-11-02
$55.83M
derived: sum of 4 quarters · filed 2022-11-02
2022-06-30$17.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
$24.49M
10-Q · filed 2022-08-08
$55.83M
derived: sum of 3 quarters · filed 2022-08-08
$55.83M
derived: sum of 4 quarters · filed 2022-11-02
2022-03-31$7.36M
10-Q · filed 2022-05-02
$38.69M
derived: sum of 2 quarters · filed 2022-05-02
$38.69M
derived: sum of 3 quarters · filed 2022-11-02
$45.63M
derived: sum of 4 quarters · filed 2022-11-02
2021-12-31$31.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
$31.34M
derived: sum of 2 quarters · filed 2022-11-02
$38.27M
derived: sum of 3 quarters · filed 2022-11-02
$31.34M
10-K · filed 2022-02-25
2021-09-30$0.00
10-Q · filed 2022-11-02
$6.94M
derived: sum of 2 quarters · filed 2022-11-02
$0.00
10-Q · filed 2022-11-02
$23.24M
10-Q · filed 2021-10-25
$5.31M
derived: sum of 4 quarters · filed 2022-11-02
2021-06-30$6.94M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
$12.28M
10-Q · filed 2022-08-08
$5.31M
derived: sum of 3 quarters · filed 2022-08-08
-$3.36M
derived: sum of 4 quarters · filed 2022-08-08
2021-03-31$5.34M
10-Q · filed 2022-05-02
-$1.63M
derived: sum of 2 quarters · filed 2022-05-02
-$10.30M
derived: sum of 3 quarters · filed 2022-05-02
-$14.21M
derived: sum of 4 quarters · filed 2022-05-02
2020-12-31-$6.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
-$15.64M
derived: sum of 2 quarters · filed 2022-02-25
-$19.55M
derived: sum of 3 quarters · filed 2022-02-25
-$14.73M
10-K · filed 2022-02-25
2020-09-30-$8.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-25
-$12.58M
derived: sum of 2 quarters · filed 2021-10-25
-$7.76M
10-Q · filed 2021-10-25
-$15.34M
derived: sum of 4 quarters · filed 2022-02-25
2020-06-30-$3.92M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-26
$908.00K
10-Q · filed 2021-07-26
-$6.67M
derived: sum of 3 quarters · filed 2022-02-25
-$369.00K
derived: sum of 4 quarters · filed 2022-02-25
2020-03-31$4.82M
10-Q · filed 2021-05-10
-$2.76M
derived: sum of 2 quarters · filed 2022-02-25
$3.55M
derived: sum of 3 quarters · filed 2022-02-25
$2.11M
derived: sum of 4 quarters · filed 2022-02-25
2019-12-31-$7.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
-$1.28M
derived: sum of 2 quarters · filed 2022-02-25
-$2.71M
derived: sum of 3 quarters · filed 2022-02-25
-$891.00K
10-K · filed 2022-02-25
2019-09-30$6.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27
$4.87M
derived: sum of 2 quarters · filed 2020-10-27
$6.69M
10-Q · filed 2020-10-27
2019-06-30-$1.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30
$386.00K
10-Q · filed 2020-07-30
2019-03-31$1.82M
10-Q · filed 2020-04-29
2018-12-31$5.50M
10-K · filed 2021-03-01
2017-12-31-$4.22M
10-K · filed 2020-03-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Immunome Inc. (IMNM)United States$2.538B-9.45
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Zai Lab Ltd (ZLAB)$2.241B-113.34